ARNI : Summary for ARNO THERAPEUTICS COM USD0.0001 - Yahoo Finance

U.S. Markets closed

Arno Therapeutics, Inc. (ARNI)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.03-0.01 (-18.92%)
At close: 3:56PM EDT
People also watch
SVONCOCPANTBMBVXBTHE
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.04
Open0.03
Bid0.00 x
Ask0.00 x
Day's Range0.02 - 0.03
52 Week Range0.02 - 0.92
Volume185,682
Avg. Volume47,392
Market Cap1.48M
Beta1.34
PE Ratio (TTM)-0.08
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wirelast month

    Arno Therapeutics Announces Plan to Deregister its Common Stock

    Arno Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced that its Board of Directors has approved a plan for the Company to file a Form 15 with the Securities and Exchange Commission in order to deregister its common stock under Section 12 of the Securities and Exchange Act of 1934....

  • Business Wire4 months ago

    Arno Therapeutics Announces Update to Onapristone Prostate Cancer Development Program

    Arno Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced that it has concluded not to enroll the remaining 3 patients in the Company’s ongoing Phase 2 clinical trial of onapristone in combination with Zytiga® in men with advanced castration-resistant prostate cancer  who have failed ...

  • Business Wire4 months ago

    Arno Therapeutics Announces Cancellation of Special Meeting of Stockholders

    Arno Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced that it has cancelled the special meeting of stockholders scheduled for December 22, 2016. The Company will consider at a later date whether to seek stockholder approval of the proposed amendments to its certificate of incorporation ...